New Assessment Tool Helps Predict Risk of Cognitive Decline

This article originally appeared here.
Share this content:
New Assessment Tool Helps Predict Risk of Cognitive Decline
New Assessment Tool Helps Predict Risk of Cognitive Decline

THURSDAY, March 19, 2015 (HealthDay News) -- A new assessment tool may be able to predict risk of mild cognitive impairment (MCI) in older adults, according to a study published online March 18 in Neurology.

V. Shane Pankratz, Ph.D., from the University of New Mexico Health Sciences Center in Albuquerque, and colleagues developed risk scores to predict risk of MCI. Baseline demographic and clinical variables from participants (aged 70 to 89 years at baseline in October 2004) in a longitudinal cohort were used to inform the risk models.

The researchers found that 401 of the 1,449 cognitively normal participants developed MCI (27.7 percent). An augmented model improved the C statistic of the basic model from 0.60 (0.58 for women and 0.62 for men) to 0.70 (0.69 for women and 0.71 for men). In the augmented model, the highest versus lowest sex-specific quartiles had an approximately seven-fold higher risk of developing MCI for both men and women. Inclusion of APOE ε4 carrier status significantly improved the model (P = 0.002).

"These models may be useful in identifying patients who might benefit from more expensive or invasive diagnostic testing, and can inform clinical trial design," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »